Standardising Clinical Caremaps: Model, Method and Graphical Notation for Caremap Specification

Standardising care can improve patient safety and outcomes, and reduce the cost of providing healthcare services. Caremaps were developed to standardise care, but contemporary caremaps are not standardised. Confusion persists in terms of terminology, structure, content and development process. Unlike existing methods in the literature, the approach, model and notation presented in this chapter pays special attention to incorporation of clinical decision points as first-class citizens within the modelling process. The resulting caremap with decision points is evaluated through creation of a caremap for women with gestational diabetes mellitus. The proposed method was found to be an effective way for comprehensively specifying all features of caremaps in a standardised way that can be easily understood by clinicians. This chapter contributes a new standardised method, model and notation for caremap content, structure and development

Mat\ue9riaux pour l’entomographie de l’Am\ue9rique du Sud. Staphylinides recueillis par MM. C. Jelski et le Baron de Nolken dans le P\ue9rou el la Nouvelle Grenade. Article III

Volume: 11Start Page: 3End Page: 3

Reducing surgical mortality in Scotland by use of the WHO Surgical Safety Checklist

Acknowledgements R. Munro and R. Black of NHS National Services Scotland, UK, provided data intelligence. B. Robson helped review this paper; A. Longmate was involved in the preliminary design of this study; J. Ingram, J. Ferbrache and SPSP managers from health boards in Scotland provided some of the information on surgical checklist implementation practices at hospitals across NHS Scotland. Data, analytical methods and study materials used may be made available to other researchers on request. The lead author affirms that the manuscript is an honest, accurate and transparent account of the study being reported. No important aspects of the study have been omitted. Any discrepancies from the study as planned (and, if relevant, registered) have been explained. This study was not funded by any individual or group. The Research Governance Department of the University of Aberdeen sponsored this project and supported the application through ethical review and data management. Disclosure: A.A.G. has received royalties from multiple publishers for writing on improving healthcare, including through use of checklists: Objetiva, Sextante (Brazil); Profile Books Ltd (British Commonwealth); Cheers Publishing Company, Commonwealth Publishing Co (People's Republic of China); Jesenski & Turk, Mizaik Knjiga, Mozaik Knjiga (Croatia); Dokoran (Czech Republic); Lindhart og Rinhoft Forlag (Denmark); Pilgrim Group (Estonia); Editions Moyen‐Courrier, Fayard, Libraire Arthème Fayard, Moyen‐Courrier (France); Radarami (Georgia), S Fischer, Verlagsgruppe Random House (Germany); Crete University Press (Greece); Tericam Kindo (Hungary); Mehta Publishing House, Penguin Random House Books (India); Gramedia Pustaka Utama, Serambi Ilmu Semesta (Indonesia); Arjmand Press (Iran); Am Oved, Modan (Israel); Einaudi Editore (Italy); Misuzu Shobo, Shinyusha Co Ltd (Japan); Janis Roze Publishers (Latvia); Vaga (Lithuania); Mime Forlag (Norway); Magnum, Znak (Poland); Lua de Papel (Portugal); Codecs, Grup Media Litera, Litera, Streamland Ltd (Romania); Slovant Publishers (Slovakia); Mladinska Knjiga (Slovenia); Antoni Bosch Editor, Editorial Empuries, Galaxia Gutenberg (Spain); Asa Editore, Bookie Publishing House, Book21, Sosoh Publishing (South Korea); Volante (Sweden); Alpina, AST (Russia); Matichon, Openworlds (Thailand); Arbeiderspers, Nieuwezijds, Uitgeverij De Arbeiderspers, Uitgeverij Nieuwezijds (the Netherlands); Domingo, Koton Kitap (Turkey); Verlagsgruppe Vivat (Ukraine); CBS Television, Henry Holt, Houghton Mifflin, Harvard Business School Press, McGraw Hill, Pearson Publishing, Public Broadcasting Service, Picador USA (USA), First News‐Tn Viet Publishing Co, Suc Manh Ngoi But Co (Vietnam); and Harper Collins (World). The authors declare no other conflict of interest.Peer reviewedPostprin

Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment

Ribavirin (RBV) is an integral part of standard-of-care hepatitis C virus (HCV) treatments and many future regimens under investigation. The pharmacokinetics (PK), safety, and tolerability of RBV in chronically HCV-infected patients with renal impairment are not well defined and were the focus of an open-label PK study in HCV-infected patients receiving RBV plus pegylated interferon. Serial RBV plasma samples were collected over 12 h on day 1 of weeks 1 and 12 from patients with moderate renal impairment (creatinine clearance [CL CR ], 30 to 50 ml/min; RBV, 600 mg daily), severe renal impairment (CL CR , <30 ml/min; RBV, 400 mg daily), end-stage renal disease (ESRD) (RBV, 200 mg daily), or normal renal function (CL CR , >80 ml/min; RBV, 800 to 1,200 mg daily). Of the 44 patients, 9 had moderately impaired renal function, 10 had severely impaired renal function, 13 had ESRD, and 12 had normal renal function. The RBV dose was reduced because of adverse events (AEs) in 71% and 53% of severe and moderate renal impairment groups, respectively. Despite this modification, patients with moderate and severe impairment had 12-hour (area under the concentration-time curve from 0 to 12 h [AUC 0–12 ]) values 36% (38,452 ng · h/ml) and 25% (35,101 ng · h/ml) higher, respectively, than those with normal renal function (28,192 ng · h/ml). Patients with ESRD tolerated a 200-mg daily dose, and AUC 0–12 was 20% lower (22,629 ng · h/ml) than in patients with normal renal function. PK modeling and simulation (M&S) indicated that doses of 200 mg or 400 mg alternating daily for patients with moderate renal impairment and 200 mg daily for patients with severe renal impairment were the most appropriate dose regimens in these patients

Effect of recrystallisation on the radioactive contamination of CaWO4 crystal scintillators

Minimising intrinsic radioactivity of crystal scintillators is of particular importance for experiments searching for rare events. We studied the impact of the crystal production process (recrystallisation) on the level of radioactive contamination of CaWO4 crystal scintillators. Several samples of single crystal scintillators were produced using the recrystallisation procedure. It is shown that this has a significant effect on the radioactive contamination of the crystals. Depending on the stage of recrystallisation the activity due to 210Po (product of 210Pb decay) varies in the range 0.031.32 Bq kg-1 while the activity of 238U varies from 0.04 to 0.33 Bq kg-1. We found that uranium is rejected by the crystal with a segregation coefficient ≈0.3. The improvement in radiopurity of CaWO4 by one order of magnitude due to recrystallisation has been demonstrated. The additional benefit of this process is the improvement in the energy resolution. A programme to develop radiopure CaWO4 crystal scintillators is discussed briefly. © 2010 Elsevier B.V. All rights reserved